About the LFB Group
Since it was formed in 1994, the LFB Group has been developing, manufacturing and marketing biological medicinal products, for serious, often rare diseases.
The LFB Group is now one of the leading European players in the field of biopharmaceuticals. LFB’s medicinal products are prescribed in hospitals, used in 3 major therapeutic areas: Immunology, Haemostasis, and Intensive Care.
The LFB group is a biopharmaceutical company, one of the rare manufacturers in the world with expertise in different bioproduction techniques, offering plasma-derived medicinal products, recombinant medicinal products and advanced therapy treatments such as cell and gene therapies. The LFB Group’s strategy is focused on international growth and an active research and development policy in its fields of therapeutic excellence.
LFB is a public company and the Group is growing in a competitive sector, with medicinal products sold in almost 60 countries.
Over 2300 employees of the LFB Group, both in France and worldwide, are totally committed to meeting the needs of hundreds of thousands of patients.
Every year, LFB’s 23 biopharmaceuticals are used to treat hundreds of thousands of patients with serious and often rare diseases.